Why Nanobiotech Pharma?

• We are the pioneers of CNP (aka Nanobacteria) Research, We developed the first and only nanobiotics and also the only diagnostic tests for CNPs. We are the only Company with effective nanobiotic therapies shown in published clinical trials to effectively treat CNP/Nanobacteria infections, reverse pathological calcification, the attendant inflammation and the plaque effects in multiple diseases. Our researchers were the scientists that discovered CNPs and and developed the diagnostic tests for CNP Antigens & Antibodies. 

• We know CNP/Nanobacteria and the idiosyncrasies/effects better than anyone else. CNP/Nanobacteria have been shown to be the cause of pathological calcification (disease-related) calcium deposits) in heart disease, arthritis, kidney disease, neurodegenerative diseases, dermatological diseases and other chronic disorders as have been published in many leading scientific/medical journals. Until studies by Mezo & Kajander, no previous research had shown the cause of pathological calcification. No process or organism has otherwise been found that produces these rock-hard calcified deposits under normal serum & blood conditions, except CNPs.

Clearly, since we developed the market, we have an advantage.

• Nanobiotech Pharma has a range of Nanobiotic compounds, NanobacTX, Urobac, Dermabac, RegenurEYES and others that consist of well known and GRAS (safe) ingredients that have been shown to convincingly eradicate nanobacteria in vitro and in vivo as published by the US Patent Office.

• Nanobiotech Pharma has license to an extensive, niche-encompassing and compelling family of related intellectual property, including proprietary diagnostics that can recognize CNP/nanobacteria in serum, blood, urine and human tissue. Recently, these diagnostics have shown that nanobacteria bind disease-causing proteins in uniquely identifiable combinations, opening new doors to the early diagnosis and differentiation of many diseases.

• Published clinical and/or scientific studies have shown that our nanobiotics are effective at treating heart disease, arteriosclerosis, atherosclerosis, BPH and prostatitis where no other treatments have previously succeeded. From our studies, we have learned valuable information about compliance, drug effectiveness, safety and the mechanisms of action of our nanobiotics. No serious safety problems have been encountered.

• Our pipeline of new therapeutics in development is one of the most unique and encompassing in the industry, focusing exclusively on curative therapies for a broad range of unmet medical needs. Unlike most, we seek to discover and develop cures,  rather than just the palliative treatment of symptoms. Relying on the strength of our pipeline and combined scientific talents, we continue to generate a steady stream of breakthroughs. Our researchers continue to work around the clock and around the globe.